Johnson & Johnson ( JNJ ) is the leading US pharma company. The firm is set to be the first pharma group to surpass $100bn in revenue in 2026 with growth underp...
Johnson & Johnson, a top US pharmaceutical firm, is forecast to exceed $100 billion in revenue by 2026, a first for any pharma group. Analysts recommend a "Buy" rating, considering JNJ an excellent portfolio option, particularly for balancing AI investments.
Market Samachar is a news aggregator. This article was originally published by seekingalpha.com. Tap the button above to read the full story on their site.